Intestinal adaptation after ileal interposition surgery increases bile acid recycling and protects against obesity related co-morbidities.

Kohli, R., Kirby, M., Setchell, K.D., Jha, P., Klustaitis, K., Woollett, L.A., Pfluger, P.T., Balistreri, W.F., Tso, P., Jandacek, R.J., Woods, S.C., Heubi, J.E., Tschoep, M.H., D'Alessio, D.A., Shroyer, N.F., Seeley, R.J.
Journal   Am J Physiol Gastrointest Liver Physiol.
Species  
Analytes Measured   GLP-1
Matrix Tested   Serum
Year   2010
Volume  
Page Numbers  
Application   Metabolic
Abstract
Surgical interposition of distal ileum into the proximal jejunum is a bariatric procedure that improves the metabolic syndrome. Changes in intestinal and hepatic physiology after ileal interposition (transposition) surgery (IIS) are not well understood. Our aim was to elucidate the adaptation of the interposed ileum, which we hypothesized, would lead to early bile acid reabsorption in the interposed ileum, thus short circuiting enterohepatic bile acid recycling to more proximal bowel segments. Rats with diet-induced obesity were randomized to IIS, with 10 cm of ileum repositioned distal to the duodenum, or sham surgery. A subgroup of sham rats was pair-fed to IIS rats. Physiological parameters were measured until 6 wk postsurgery. IIS rats ate less and lost more weight for the first 2 wk postsurgery. At study completion, body weights were not different, but IIS rats had reversed components of the metabolic syndrome. The interposed ileal segment adapted to a more jejunum-like villi length, mucosal surface area, and GATA4/ILBP mRNA. The interposed segment retained capacity for bile acid reabsorption and anorectic hormone secretion with the presence of ASBT and glucagon-like-peptide-1-positive cells in the villi. IIS rats had reduced primary bile acid levels in the proximal intestinal tract and higher primary bile acid levels in the serum, suggesting an early and efficient reabsorption of primary bile acids. IIS rats also had increased taurine and glycine-conjugated serum bile acids and reduced fecal bile acid loss. There was decreased hepatic Cyp27A1 mRNA with no changes in hepatic FXR, SHP, or NTCP expression. IIS protects against the metabolic syndrome through short-circuiting enterohepatic bile acid recycling. There is early reabsorption of primary bile acids despite selective "jejunization" of the interposed ileal segment. Changes in serum bile acids or bile acid enterohepatic recycling may mediate the metabolic benefits seen after bariatric surgery.

View Publications

Related Products

U-PLEX Diabetes Combo 1 (mouse)
C-Peptide, GLP-1 (total), Glucagon, Insulin, Leptin, PYY (total) | Mouse
Multiplex
U-PLEX Metabolic 3-Plex Combo 1 (mouse)
GLP-1 (total), Glucagon, Insulin | Mouse
Multiplex
U-PLEX Microbiome Combo 1 (human)
Ghrelin (total), GLP-1 (total), Glucagon, Insulin, Leptin, PP, PYY (total) | Human
Multiplex
U-PLEX Diabetes Combo 1 (rat)
C-Peptide, GLP-1 (total), Glucagon, Insulin, Leptin, PYY (total) | Rat
Multiplex
U-PLEX Metabolic 3-Plex Combo 1 (rat)
GLP-1 (total), Glucagon, Insulin | Rat
Multiplex
U-PLEX Diabetes Combo 1 (human)
C-Peptide, GIP (total), GLP-1 (total), Glucagon, Insulin, Leptin, PYY (total) | Human
Multiplex
U-PLEX Custom Metabolic Group 1 (rat) 384-well Assays
Rat
Multiplex
U-PLEX Mouse GLP-1 (total) 384-Well Assay
GLP-1 (total) | Mouse
Singleplex
U-PLEX Rat GLP-1 (total) 384-Well Assay
GLP-1 (total) | Rat
Singleplex
U-PLEX Custom Metabolic Group 1 (mouse) 384-well Assays
BAFF, BCA-1/BLC, BDNF, CD40/TNFRSF5, C-Peptide, Eotaxin, EPO, FGF-21, Ghrelin (active), Ghrelin (total), GLP-1 (active), GLP-1 (inactive), GLP-1 (total), Glucagon, GM-CSF, IFN-α, IFN-β, IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-17A/F, IL-17C, IL-17E/IL-25, IL-17F, IL-21, IL-22, IL-23, IL-27p28/IL-30, IL-31, IL-33, Insulin, IP-10, KC/GRO, Leptin, MCP-1, MCP-5/CCL12, MDC, MIP-1α, MIP-1β, MIP-2, MIP-3α, MMP-9 (total), PYY (total), RANTES, TARC, TNF-α, VEGF-A | Mouse
Multiplex
U-PLEX Human GLP-1 (total) 384-well Assay
GLP-1 (total) | Human
Singleplex
U-PLEX Custom Metabolic Group 1 (human) 384-well Assays
BAFF, BDNF, β-NGF, C-Peptide, CTACK, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, EPO, FGF-21, FGF-23, FLT3L, Fractalkine, FSH, G-CSF, Ghrelin (active), Ghrelin (total), GIP (active), GIP (inactive), GIP (total), GLP-1 (active), GLP-1 (inactive), GLP-1 (total), Glucagon, GM-CSF, GRO-α, I-309, IFN-α2a, IFN-β, IFN-γ, IL-1α, IL-1β, IL-1RA, IL-2, IL-2Rα, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-17A/F, IL-17C, IL-17D, IL-17E/IL-25, IL-17F, IL-18, IL-21, IL-22, IL-23, IL-27, IL-29/IFN-λ1, IL-31, IL-33, Insulin, IP-10, Leptin, Luteinizing Hormone (LH), MCP-1, MCP-2, MCP-4, M-CSF, MDC, MIF, MIP-1α, MIP-5, PP, Proinsulin, PYY (total), SDF-1α, TARC, TNF-α, TNF-β, TPO, TRAIL, TSLP, VEGF-A, YKL-40 | Human
Multiplex
U-PLEX Mouse GLP-1 (total) Assay
GLP-1 (total) | Mouse
Singleplex
U-PLEX Rat GLP-1 (total) Assay
GLP-1 (total) | Rat
Singleplex
U-PLEX Human GLP-1 (total) Assay
GLP-1 (total) | Human
Singleplex
U-PLEX Custom Metabolic Group 1 (rat) Assays
Rat
Multiplex
U-PLEX Custom Metabolic Group 1 (mouse) Assays
Mouse
Multiplex
U-PLEX Metabolic Combo 1 (rat)
BDNF, C-Peptide, FGF-21, Ghrelin (active), Ghrelin (total), GLP-1 (active), GLP-1 (inactive), GLP-1 (total), Glucagon, Insulin, Leptin, PYY (total) | Rat
Multiplex
U-PLEX Metabolic Combo 1 (mouse)
BAFF, BDNF, C-Peptide, FGF-21, Ghrelin (active), Ghrelin (total), GLP-1 (active), GLP-1 (inactive), GLP-1 (total), Glucagon, Insulin, Leptin, PYY (total) | Mouse
Multiplex
U-PLEX Obesity Combo 2 (rat)
C-Peptide, Ghrelin (total), GLP-1 (total), Insulin, Leptin, PYY (total) | Rat
Multiplex
U-PLEX Obesity Combo 2 (mouse)
C-Peptide, Ghrelin (total), GLP-1 (total), Insulin, Leptin, PYY (total) | Mouse
Multiplex
U-PLEX Custom Metabolic Group 1 (human) Assays
BAFF, BDNF, β-NGF, C-Peptide, CTACK, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, EPO, FGF-21, FGF-23, FLT3L, Fractalkine, FSH, G-CSF, Ghrelin (active), Ghrelin (total), GIP (active), GIP (inactive), GIP (total), GLP-1 (active), GLP-1 (inactive), GLP-1 (total), Glucagon, GM-CSF, GRO-α, I-309, IFN-α2a, IFN-β, IFN-γ, IL-1α, IL-1β, IL-1RA, IL-2, IL-2Rα, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-17A/F, IL-17C, IL-17D, IL-17E/IL-25, IL-17F, IL-18, IL-21, IL-22, IL-23, IL-27, IL-29/IFN-λ1, IL-31, IL-33, Insulin, IP-10, Leptin, Luteinizing Hormone (LH), MCP-1, MCP-2, MCP-4, M-CSF, MDC, MIF, MIP-1α, MIP-5, PP, Proinsulin, PYY (total), SDF-1α, TARC, TNF-α, TNF-β, TPO, TRAIL, TSLP, VEGF-A, YKL-40 | Human
Multiplex
U-PLEX GLP-1 (total) Antibody Set (5 Plate Size)
GLP-1 (total) | Human, Mouse, Rat
U-PLEX Metabolic Combo 1 (human)
BAFF, BDNF, β-NGF, C-Peptide, FGF-21, FGF-23, FSH, Ghrelin (active), Ghrelin (total), GIP (active), GIP (inactive), GIP (total), GLP-1 (active), GLP-1 (inactive), GLP-1 (total), Glucagon, Insulin, Leptin, Luteinizing Hormone (LH), PP, Proinsulin, PYY (total) | Human
Multiplex
U-PLEX Obesity Combo 2 (human)
C-Peptide, FGF-23, Ghrelin (total), GLP-1 (total), Insulin, Leptin, PYY (total) | Human
Multiplex
V-PLEX GLP-1 (total) Kit
GLP-1 (total) | Human, Mouse, Non-human primate, Rat, Canine
Singleplex
V-PLEX Plus GLP-1 (total) Kit
GLP-1 (total) | Human, Mouse, Non-human primate, Rat, Canine
Singleplex
GLP-1 (total) Control Pack
GLP-1 (total) | Human, Mouse, Non-human primate, Rat, Canine
GLP-1 (total) Antibody
GLP-1 (total) | Human
Browse Our Products

By Analytes
By Applications
Search
Meso Scale Japan 株式会社